MXPA03005699A - Derivados de tiazol para tratar trastornos relacionados con ppar. - Google Patents

Derivados de tiazol para tratar trastornos relacionados con ppar.

Info

Publication number
MXPA03005699A
MXPA03005699A MXPA03005699A MXPA03005699A MXPA03005699A MX PA03005699 A MXPA03005699 A MX PA03005699A MX PA03005699 A MXPA03005699 A MX PA03005699A MX PA03005699 A MXPA03005699 A MX PA03005699A MX PA03005699 A MXPA03005699 A MX PA03005699A
Authority
MX
Mexico
Prior art keywords
related disorders
thiazole derivatives
treating ppar
ppar related
treating
Prior art date
Application number
MXPA03005699A
Other languages
English (en)
Spanish (es)
Inventor
Cadilla Rodolfo
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA03005699A publication Critical patent/MXPA03005699A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA03005699A 2000-12-20 2001-12-19 Derivados de tiazol para tratar trastornos relacionados con ppar. MXPA03005699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
PCT/US2001/049230 WO2002062774A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders

Publications (1)

Publication Number Publication Date
MXPA03005699A true MXPA03005699A (es) 2003-10-06

Family

ID=9905492

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005699A MXPA03005699A (es) 2000-12-20 2001-12-19 Derivados de tiazol para tratar trastornos relacionados con ppar.

Country Status (27)

Country Link
EP (1) EP1343773B1 (https=)
JP (1) JP4209681B2 (https=)
KR (1) KR100815022B1 (https=)
CN (1) CN1252057C (https=)
AR (1) AR035522A1 (https=)
AT (1) ATE344253T1 (https=)
AU (1) AU2002246713B2 (https=)
BR (1) BR0116370A (https=)
CA (1) CA2432188A1 (https=)
CY (1) CY1105915T1 (https=)
CZ (1) CZ20031737A3 (https=)
DE (1) DE60124302T2 (https=)
DK (1) DK1343773T3 (https=)
ES (1) ES2274914T3 (https=)
GB (1) GB0031107D0 (https=)
HU (1) HUP0400837A3 (https=)
IL (2) IL156436A0 (https=)
MX (1) MXPA03005699A (https=)
MY (1) MY136685A (https=)
NO (1) NO20032801L (https=)
NZ (1) NZ526543A (https=)
PL (1) PL365797A1 (https=)
PT (1) PT1343773E (https=)
SI (1) SI1343773T1 (https=)
TW (1) TWI292759B (https=)
WO (1) WO2002062774A1 (https=)
ZA (1) ZA200304679B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU5884101A (en) 2000-05-26 2001-12-03 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2003217274A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
RU2005141516A (ru) 2003-06-06 2007-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные анилина
KR100796093B1 (ko) 2003-07-02 2008-01-21 에프. 호프만-라 로슈 아게 티아졸 고리로 치환된 인돌릴 유도체 및 ppar조절제로서 그의 용도
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
AU2005320387A1 (en) * 2004-12-31 2006-07-06 Seoul National University Industry Foundation Organoselenium containing compounds and their use
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
WO2006091047A1 (en) 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma, Inc. ácidos fenóxi acéticos como ativadores de ppar delta
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CN101595089A (zh) 2006-12-02 2009-12-02 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
JP5367584B2 (ja) * 2007-01-08 2013-12-11 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖因子活性化受容体δリガンドチアゾール化合物及びこれを含有する医薬、化粧品及び健康食品組成物
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
JP2004518702A (ja) 2004-06-24
DE60124302T2 (de) 2007-05-03
DK1343773T3 (da) 2007-02-05
AU2002246713B2 (en) 2004-09-09
NO20032801L (no) 2003-08-04
DE60124302D1 (de) 2006-12-14
EP1343773A1 (en) 2003-09-17
KR20030072571A (ko) 2003-09-15
CN1252057C (zh) 2006-04-19
CY1105915T1 (el) 2011-04-06
ES2274914T3 (es) 2007-06-01
TWI292759B (en) 2008-01-21
HUP0400837A2 (hu) 2004-08-30
ZA200304679B (en) 2004-10-04
HUP0400837A3 (en) 2007-11-28
IL156436A0 (en) 2004-01-04
NO20032801D0 (no) 2003-06-19
WO2002062774A1 (en) 2002-08-15
EP1343773B1 (en) 2006-11-02
CA2432188A1 (en) 2002-08-15
ATE344253T1 (de) 2006-11-15
CN1527822A (zh) 2004-09-08
JP4209681B2 (ja) 2009-01-14
HK1059925A1 (en) 2004-07-23
MY136685A (en) 2008-11-28
PT1343773E (pt) 2007-02-28
PL365797A1 (en) 2005-01-10
GB0031107D0 (en) 2001-01-31
SI1343773T1 (sl) 2007-04-30
IL156436A (en) 2008-06-05
BR0116370A (pt) 2003-12-09
KR100815022B1 (ko) 2008-03-18
AR035522A1 (es) 2004-06-02
CZ20031737A3 (cs) 2003-10-15
NZ526543A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
MXPA03005699A (es) Derivados de tiazol para tratar trastornos relacionados con ppar.
AU8181701A (en) Benzothiazole derivatives
IL155093A0 (en) Morpholin-acetamide derivatives for the treatment on inflammatory diseases
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
AU3740101A (en) 2,4-disubstituted thiazolyl derivatives
AU2001238472A1 (en) Method for treating parathyroid disorders
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
EP1328186A4 (en) METHODS OF TREATING VARIOUS EYES DISEASES
MXPA03003176A (es) Derivados de piridinona para tratamiento de ateroesclerosis.
ZA200202542B (en) Treating sleep disorders using desloratadine.
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
TR199802765A3 (tr) Tiyazol türevleri.
IL152190A0 (en) Substituted styryl benzylsulfones for treating proliferative disorders
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
MXPA03000838A (es) Derivados 4-, 5-, 6- y 7-indol utiles para el tratamiento de transtornos del snc.
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.
AU1603401A (en) Pyranoindoles for treating glaucoma
ZA200202841B (en) Apparatus for treating fluids.
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.

Legal Events

Date Code Title Description
FG Grant or registration